Wipro, CloudGenix Partner to Deliver Managed SD-WAN Services
Wipro Limited(NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company and CloudGenix Inc., a leading provider of Software-Defined Wide Area Networking (SD-WAN) products, today announced a partnership to offer open and managed SD-WAN services. Termed as WANFreedom, the service allows enterprise customers to rapidly deploy cloud, SaaS (Software as a Service) and data center applications over any combination of MPLS (Multiprotocol Label Switching), Internet broadband and LTE (Long Term Evolution) networks, thereby enabling a rich user experience and IT infrastructure cost optimization.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170926006047/en/
Traditional WAN products based on proprietary hardware and complex routing protocols result in substantial dependencies and inhibit cloud adoption. With WANFreedom, customers will be freed from dependencies on WAN transport, proprietary hardware routers, networking complexity, therefore freeing up IT teams to focus on rapidly delivering business value.
Over the next five years, SD-WAN sales are forecast to grow at a 69.6% compound annual growth rate, reaching $8.05 billion in 2021, according to the IDC Worldwide SD-WAN Forecast: 2017–2021 (doc #US42904317, July 2017) report. This growth is fueled by rapid adoption of cloud, SaaS and data center applications, the commoditization of connectivity boosted by low-cost and high-capacity broadband availability, and the digitization of remote offices.
Kiran Desai, Senior Vice President & Global Head, Global Infrastructure Services, Wipro Limited said, “By partnering with CloudGenix, Wipro now offers its customers an end-to-end managed WAN, delivering a host of benefits including WAN transport independence, the ability to seamlessly integrate multiple telecom and network carriers and WAN types, improved WAN availability, uncompromised access to cloud, SaaS and rich media applications, elimination of proprietary hardware routers, and significant cost savings. These capabilities provide enterprises the freedom to adopt cloud, UCaaS (Unified Communications as a Service), SaaS and other modern applications without compromising security, performance, or visibility.”
Kumar Ramachandran, CEO, CloudGenix said, “Wipro is a recognized global leader in deploying, managing, and operationalizing network infrastructure. Wipro’s WAN assessment and prescriptive service delivery model ensures customers gain instant time to value without needing to ‘rip and-replace’ their legacy WAN infrastructure.”
Wipro’s SD-WAN capabilities meet enterprise customers’ digital business needs while ensuring robust performance, security and compliance in line with their business application policies. Supported by its Software Defined Everything (SDx) Center Of Excellence and ServiceNXT, a next-generation managed services framework, Wipro’s enterprise assessment and consultancy services ensure efficient delivery of SD-WAN solution for clients.
CloudGenix’s SD-WAN is powered by CloudGenix AppFabric that enables a self-healing network built on machine learning, which ensures faster time to market and better response to business needs.
About Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading global information technology, consulting and business process services company. We harness the power of cognitive computing, hyper-automation, robotics, cloud, analytics and emerging technologies to help our clients adapt to the digital world and make them successful. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability and good corporate citizenship, we have over 160,000 dedicated employees serving clients across six continents. Together, we discover ideas and connect the dots to build a better and a bold new future.
About CloudGenix
CloudGenix (www.cloudgenix.com) is the software-defined wide-area network (SD-WAN) leader, revolutionizing networking by transforming legacy WANs into a radically simplified, secure, application-defined fabric and unified hybrid WAN. Enabling application-specific, service-level agreements (SLAs), CloudGenix controls network application performance based upon application-performance SLAs and business priority. CloudGenix ION (Instant-On Network) simplifies how WANs are designed and managed, enabling customers to build “networks without networking,” and achieve more than twice the performance at less than half the cost while extending data center-class security to the network edge. Founded in 2013 by a team that has delivered industry-leading products in networking, SDN, cloud, security and web-scale applications, CloudGenix serves world-class financial services, legal, retail and technology organizations.
Forward-looking and Cautionary Statements
Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property, and general economic conditions affecting our business and industry. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170926006047/en/
Contact information
Wipro Limited
Prathibha Das
prathibha.das@wipro.com
or
CloudGenix
Joel
Christner
pr@cloudgenix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 22:30:00 EEST | Press release
Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 21:45:00 EEST | Press release
Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of European enterprises, providing a framework for high performance in even the most complex, secure environments. “With about 6 million developers across Europe, users deserve infrastructure that meets them where they are,” said Varun Mohan, CEO of Windsurf. “The demand for secure AI-powered development is undeniable and by launching this GPU cluster, we aim to b
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 20:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization journey, allowing developers to focus on building engaging games, not commerce infrastructure. This SDK connects three
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 18:00:00 EEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom